Display Settings:

Format

Send to:

Choose Destination

    Eur Arch Otorhinolaryngol. 2009 Nov;266(11):1767-73. Epub 2009 Jan 22.

    Nasopharyngeal carcinoma in adolescents: a retrospective review of 42 patients.

    Afqir S, Ismaili N, Alaoui K, Ahid S, Lotz JP, Horn E, Bouhafa T, Abouqal R, Errihani H.

    Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco.

    The aim of the present study was to evaluate the characteristics and outcome of adolescent patients with nasopharyngeal carcinoma (NPC) disease. The study concerned 46 pediatric NPC patients treated during the period 1999-2002 at the National Institute of Oncology, Rabat. The median age of the patients was 16 years. The male/female ratio was 2.8/1. Histologically, all patients had undifferentiated carcinoma. A total of 93% presented nodal metastasis. Four (9%) had distant metastasis. All patients received neoadjuvant multiagent chemotherapy containing cisplatin, followed by radiotherapy. Kaplan-Meier curves were used to evaluate prognostic factors. The log-rank test was used to evaluate the differences between the groups. While none of the patients had locoregional failure, nine patients (29%) developed distant metastasis. The disease-free survival and overall survival (OS) rate for the entire group were 73 and 41%, respectively. Responders to chemotherapy had superior OS (P < 0.001). We suggest that combined modality management using multi-agent chemotherapy and RT as an effective treatment of NPC disease which will achieve satisfactory locoregional control and OS of NPC pediatric patients. Response to chemotherapy was an important prognostic factor.

    PMID: 19159940 [PubMed - in process]

    Supplemental Content

    Click here to read Click here to read Click here to read

    Patient drug information

    • Cisplatin (Platinol®-AQ)

      Your doctor has ordered the drug cisplatin to help treat your illness. The drug is given by injection into a vein.